Trial Radar
Sign in

Study record

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

NCT05327894

RecruitingPhase 3

Sponsor: Princess Maxima Center for Pediatric Oncology

Conditions: Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

Interventions: Blinatumomab, Blinatumomab

Countries: Argentina, Australia, Austria, Belgium, Czechia, Denmark, Finland, France

This study is a treatment protocol with blinatumomab for infants under 1 year old who are diagnosed with acute lymphoblastic leukemia with a specific unfavorable genetic alteration. The purpose of the study is to improve the outcome of this disease in infants.

Study history thread

Detected changes and registry snapshots from Trial Radar syncs

1 events · 1 snapshots

1 recorded events1 registry snapshotsTracked since Jul 13, 2026Official CT.gov history
  1. Jul 13, 2026
    New TrialNotable

    Princess Maxima Center for Pediatric Oncology started Phase 3 Acute Lymphoblastic Leukemia trial

    Registry state after update: Recruiting · Phase 3 · 24 countries

← Back to dashboard